The stock of Opexa Therapeutics Inc (NASDAQ:OPXA) is a huge mover today! About 392,499 shares traded hands or 565.93% up from the average. Opexa Therapeutics Inc (NASDAQ:OPXA) has risen 77.00% since March 4, 2016 and is uptrending. It has outperformed by 68.96% the S&P500.
The move comes after 6 months positive chart setup for the $29.01 million company. It was reported on Oct, 7 by Barchart.com. We have $7.70 PT which if reached, will make NASDAQ:OPXA worth $27.85M more.
Analysts await Opexa Therapeutics Inc (NASDAQ:OPXA) to report earnings on November, 8. They expect $-0.35 earnings per share, up 16.67% or $0.07 from last year’s $-0.42 per share. After $-0.30 actual earnings per share reported by Opexa Therapeutics Inc for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.
Opexa Therapeutics Inc (NASDAQ:OPXA) Ratings Coverage
Out of 2 analysts covering Opexa Therapeutics (NASDAQ:OPXA), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Opexa Therapeutics has been the topic of 2 analyst reports since September 28, 2015 according to StockzIntelligence Inc. On Wednesday, November 4 the stock rating was initiated by Chardan Capital Markets with “Buy”. The stock of Opexa Therapeutics Inc (NASDAQ:OPXA) has “Buy” rating given on Monday, September 28 by Maxim Group.
According to Zacks Investment Research, “Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company’s lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes.”
More news for Opexa Therapeutics Inc (NASDAQ:OPXA) were recently published by: Quotes.Wsj.com, which released: “News Opexa Therapeutics Inc.OPXA” on February 12, 2011. Marketwired.com‘s article titled: “Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides …” and published on August 11, 2016 is yet another important article.
OPXA Company Profile
Opexa Therapeutics, Inc. (Opexa), incorporated on March 15, 1991, is a biopharmaceutical company. The Firm is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Company’s T-cell technology. The Company’s product candidates include Tcelna and OPX-212.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.